RBC Bioscience

RBC Bioscience Debt/EBITDA

The Total Debt to EBITDA Ratio of RBC Bioscience (6848.TWO) as of Oct 17, 2026 is 13.37. In the previous year, Total Debt to EBITDA Ratio was 32.44 — a change of -58.80% (lower).

Debt/EBITDA

13.37

YoY

-58.80%

Last updated:

Total Debt to EBITDA Ratio of RBC Bioscience is 2024 13.37 . Total Debt to EBITDA Ratio of RBC Bioscience was 2023 32.44 . It decreases by -58.80% lower compared to the previous year.

The RBC Bioscience Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
3.40 TWD
Jan 1, 2019
4.86 TWD
Jan 1, 2020
0.64 TWD
Jan 1, 2021
10.51 TWD
Jan 1, 2022
62.16 TWD
Jan 1, 2023
32.44 TWD
Jan 1, 2024
13.37 TWD
The RBC Bioscience Debt/EBITDA history
YEARDebt/EBITDAYoY
13.37-58.80%
32.44-47.81%
62.16+491.33%
10.51+1,543.78%
0.64-86.84%
4.86+42.81%
3.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp, based in Taipei, Taiwan, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company manufactures reagents and devices for life science and molecular diagnosis, including instruments with ultraviolet sterilization systems and disposable reagent strips for nucleic acid extraction. Its products, featuring cellulose-embedded magnetic beads, purify DNA and RNA from various sources for diagnostic and forensic applications. Listed on 25 October 2021, RBC Bioscience serves markets requiring advanced molecular analysis tools. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

Total Debt to EBITDA Ratio of RBC Bioscience is 13.37 in 2024.

Total Debt to EBITDA Ratio of RBC Bioscience changed from 32.44 to 13.37, representing a -58.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's RBC Bioscience with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — RBC Bioscience

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — RBC Bioscience